SOLICITATION NOTICE
R -- Regulatory Support for FDA Pre-IND Meeting: QGRFT for the Prevention of SARS-CoV-2 Infection
- Notice Date
- 6/9/2020 12:26:47 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95020Q00145
- Response Due
- 6/17/2020 8:59:00 AM
- Archive Date
- 07/02/2020
- Point of Contact
- Kimberly Espinosa
- E-Mail Address
-
kimberly.espinosa@nih.gov
(kimberly.espinosa@nih.gov)
- Small Business Set-Aside
- SBA Total Small Business Set-Aside (FAR 19.5)
- Description
- The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) requires regulatory and operational support for a pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA). This pre-IND application meeting is for the preclinical development of Q-Griffithsin (QGRFT), which may have therapeutic value as a preventative against SARS-CoV-2, the causative agent of the current COVID-19 pandemic. QGRFT data is proprietary to NCATS� collaborators at the University of Louisville Research Foundation (ULRF) and the contractor must work collaboratively with ULRF and NCATS throughout the entire period of performance. Due to the urgency of supporting the development of treatment for COVID-19, the awardee must be capable of beginning work with QGRFT immediately upon contract execution. See attached Request for Quotations, Statement of Work, and related attachments for complete requirement details.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/a9479739de8c41eb9213acfb63aafa7e/view)
- Record
- SN05684429-F 20200611/200609230141 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |